AFFILIATIONS
1 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China;, shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China., SHANGHAI, China
2 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China;, shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China., SHANGHAI, China
3 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China;, shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China., SHANGHAI, China
4 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China;, shanghai, China
5 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China;, shanghai, China
6 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China;, shanghai, China
7 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China;, shanghai, China
8 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China;, shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China., SHANGHAI, China
9 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China;, shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai 200025, China., SHANGHAI, China
ABSTRACT
Introduction: Zanubrutinib, a next-generation Bruton tyrosine kinase (BTK) inhibitor, has shown efficacy in B-cell malignancies. However, data on zanubrutinib-based combination regimens with minimal residual disease (MRD)-guided treatment decisions in chronic lymphocytic leukemia (CLL) remain limited. This investigator-initiated, single-arm, single-center phase III study evaluated the efficacy and safety of zanubrutinib-bendamustine combination followed by MRD-guided zanubrutinib monotherapy in treatment-naïve (TN) CLL.
Methods: Eligible patients were aged 18–64 years with TN CLL requiring treatment per iwCLL 2018 criteria and ECOG performance status 0–2 (ECOG 3 permitted if CLL-related). Patients received zanubrutinib 160 mg twice daily orally plus bendamustine 90 mg/m² intravenously on days 1–2 for 6 cycles (ZB-stage). After cycle 6 (C6), subsequent therapy was MRD-guided: patients achieving undetectable MRD (uMRD, ≤0.01%) discontinued therapy, while MRD-positive patients continued zanubrutinib monotherapy maintenance. Primary endpoints were overall response rate (ORR) and complete response (CR) rate in the intention-to-treat (ITT) population per iwCLL 2018 criteria. Secondary endpoints included progression-free survival (PFS), overall survival (OS), peripheral blood MRD (PB-MRD) negativity, and safety per NCI-CTCAE v5.0. The study is registered at ClinicalTrials.gov (NCT03336333) and is closed to recruitment.
Results: 35 patients were enrolled (median age 57 years [range, 44–65]; male:female 1.3:1; ECOG 0: 91.4%). By CLL-IPI, 40%, 31.4%, and 28.4% were at low, intermediate, and high risk. Cytogenetics/molecular features: TP53 mutation 5.7%, del(17p) 5.7%, concurrent TP53 mutation/del(17p) 8.6%, del(11q) 8.6%, del(13q) 40%, unmutated IGHV 34.3%. Comorbidities included type 2 diabetes mellitus (14.3%) and hypertension (22.9%). With a median follow-up of 31 months (IQR, 23–37), estimated 46-month OS was 97.1% and 41-month PFS was 97.1%; median OS and PFS were not reached (NR). One death from progressive disease (PD) occurred. For del(17p)/TP53-negative (n=32) vs. -positive (n=3) patients, 41-month PFS was 100% vs. 66.7%. ORR was 100% (35/35). At final evaluation, 16 (45.7%) achieved CR/CRi (15 CR, 1 CRi) and 19 (54.3%) had nPR/PR (15 PR, 4 nPR). Treatment completion rates were 94.3% at C3 and 85.7% at C6; discontinuations/transitions included monotherapy transition after C1 (n=1), gastrointestinal stromal tumor treatment after C3 (n=1), and return to local hospital for monotherapy after C3 (n=3). Dynamic PB-MRD analysis showed uMRD (≤0.01%) rates of 21.2% (7/33) at C3 and 28.1% (9/32) at C6. CR-uMRD rates were 40.0% (6/15) at C3 and 43.8% (7/16) at C6 vs. PR-uMRD rates of 5.0% (1/20) at C3 and 10.5% (2/19) at C6. Regarding safety, neutropenia was the most frequent hematologic toxicity (71.4% ZB-stage vs. 37.0% monotherapy). Grade 3–4 AEs included neutropenia (34.3% vs. 7.4%), thrombocytopenia (8.6% vs. 0%), lung infection (8.6% vs. 11.1%), and hypertension (5.7% vs. 0%; ZB-stage only). Non-hematologic toxicities—rash (37.1% vs. 22.2%) and hemorrhage (37.1% vs. 7.4%)—were more frequent during ZB-stage. The overall safety profile was manageable.
Conclusions: Zanubrutinib-bendamustine combination with MRD-guided zanubrutinib monotherapy demonstrated 100% ORR, favorable PFS and OS, and deepening MRD negativity in TN CLL, including patients with high-risk cytogenetics. The MRD-guided approach enabled treatment discontinuation in uMRD achievers. The safety profile was manageable with predominantly combination-phase hematologic toxicities. Longer follow-up is warranted to assess durability of responses. (NCT03336333)